RU2007129845A - Местное лечение костных дефектов с помошью вмр или ртн, высвобождаемых из матрикса - Google Patents
Местное лечение костных дефектов с помошью вмр или ртн, высвобождаемых из матрикса Download PDFInfo
- Publication number
- RU2007129845A RU2007129845A RU2007129845/15A RU2007129845A RU2007129845A RU 2007129845 A RU2007129845 A RU 2007129845A RU 2007129845/15 A RU2007129845/15 A RU 2007129845/15A RU 2007129845 A RU2007129845 A RU 2007129845A RU 2007129845 A RU2007129845 A RU 2007129845A
- Authority
- RU
- Russia
- Prior art keywords
- pth
- matrix
- composition
- domain
- use according
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title claims 24
- 210000000988 bone and bone Anatomy 0.000 title claims 4
- 239000000203 mixture Substances 0.000 claims 21
- 239000000758 substrate Substances 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 230000003190 augmentative effect Effects 0.000 claims 7
- 239000002872 contrast media Substances 0.000 claims 5
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 5
- 108060008539 Transglutaminase Proteins 0.000 claims 4
- 230000000269 nucleophilic effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102000003601 transglutaminase Human genes 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 108010049003 Fibrinogen Proteins 0.000 claims 3
- 102000008946 Fibrinogen Human genes 0.000 claims 3
- 108090000190 Thrombin Proteins 0.000 claims 3
- 230000000975 bioactive effect Effects 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229940012952 fibrinogen Drugs 0.000 claims 3
- 229960004072 thrombin Drugs 0.000 claims 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 2
- 108010000196 Factor XIIIa Proteins 0.000 claims 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 229960001025 iohexol Drugs 0.000 claims 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims 2
- KZYHGCLDUQBASN-UHFFFAOYSA-N 1-n,1-n,3-n,3-n,5-n,5-n-hexakis(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3,5-tricarboxamide Chemical compound OCCN(CCO)C(=O)C1=C(I)C(C(=O)N(CCO)CCO)=C(I)C(C(=O)N(CCO)CCO)=C1I KZYHGCLDUQBASN-UHFFFAOYSA-N 0.000 claims 1
- OQHLOKBHRXMXLD-UHFFFAOYSA-N 5-[3-[3-[3,5-bis[2,3-dihydroxypropyl(methyl)carbamoyl]-2,4,6-triiodoanilino]-3-oxopropyl]sulfanylpropanoylamino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(C(=O)N(CC(O)CO)C)=C(I)C(NC(=O)CCSCCC(=O)NC=2C(=C(C(=O)N(C)CC(O)CO)C(I)=C(C(=O)N(C)CC(O)CO)C=2I)I)=C1I OQHLOKBHRXMXLD-UHFFFAOYSA-N 0.000 claims 1
- 208000017234 Bone cyst Diseases 0.000 claims 1
- 206010061728 Bone lesion Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 claims 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims 1
- 238000006845 Michael addition reaction Methods 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960004359 iodixanol Drugs 0.000 claims 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims 1
- 229960004647 iopamidol Drugs 0.000 claims 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims 1
- 229960000824 iopentol Drugs 0.000 claims 1
- IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002603 iopromide Drugs 0.000 claims 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims 1
- -1 iorneprol Chemical compound 0.000 claims 1
- 229950011065 iosimide Drugs 0.000 claims 1
- 229950011097 iotasul Drugs 0.000 claims 1
- 229960003182 iotrolan Drugs 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000554 metrizamide Drugs 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (30)
1. Применение композиции, содержащей биоактивный фактор, выбранный из группы, состоящей из PTH и BMP, или гибридного пептида, содержащего PTH или BMP в первом домене, и субстрат, способный образовывать ковалентные поперечные связи, во втором домене, где композиция способна к образованию матрикса в участке кости, требующем лечения, для производства лекарственного средства для местного лечения участков костей, имеющих поражения.
2. Применение по п.1, где гибридный пептид образует ковалентные связи с матриксом в процессе его формирования.
3. Применение по п.1 или 2, где композиция, способная к образованию матрикса, предназначена для инъекции.
4. Применение по п.1 или 2, где участки костей, имеющих поражения, выбраны из группы, состоящей из участков костей, пораженных остеопорозом, костными кистами и костными опухолями.
5. Применение по п.1 или 2, где гибридный пептид дополнительно содержит участок деградации между первым и вторым доменом.
6. Применение по п.1 или 2, где PTH выбран из группы, состоящей из PTH1-84, PTH1-28, PTH1-34, PTH1-31 и PTH1-25.
7. Применение по п.6, где PTH представляет собой PTH1-34.
8. Применение по п.1 или 2, где BMP представляет собой BMP2 или BMP7.
9. Применение по п.1 или 2, где второй домен гибридного пептида содержит домен субстрата трансглутаминазы.
10. Применение по п.9, где домен субстрата трансглутаминазы представляет собой домен субстрата фактора XIIIa.
11. Применение по п.1 или 2, где композиция, способная к образованию матрикса, содержит фибриноген, тромбин, и источник кальция.
12. Применение по п.1 или 2, где матрикс образуется в результате реакции присоединения Майкла между первой исходной молекулой, содержащей n нуклеофильных групп, и второй исходной молекулой, содержащей m электрофильных групп, где n и m, по меньшей мере, равны двум, а сумма n+m составляет по меньшей мере пять.
13. Применение по п.12, где электрофильные группы представляют собой конъюгированные ненасыщенные группы, а нуклеофильные группы выбраны из группы, состоящей из тиолов и аминов.
14. Применение по п.12, где исходные компоненты представляют собой функционализированные полиэтиленгликоли.
15. Применение по п.1 или 2, где второй домен гибридного пептида содержит по меньшей мере один цистеин.
16. Применение по п.1 или 2, где композиция, способная к образованию матрикса, содержит более одного компонента, и где композиция предоставляется в виде набора, в котором, по меньшей мере, один из компонентов композиции, способных к образованию матрикса, хранится отдельно от других компонентов композиции.
17. Применение по п.16, где набор дополнительно содержит фермент, катализирующий образование поперечных связей.
18. Композиция, включающая
i) композицию, способную к образованию матрикса в физиологических условиях, выбранную из группы, состоящей из композиции, содержащей фибриноген, тромбин и источник кальция; и/или композиции, содержащей первую исходную молекулу, содержащую n нуклеофильных групп, и вторую исходную молекулу, содержащую m электрофильных групп, где n и m, по меньшей мере, равны двум, а сумма n+m составляет по меньшей мере пять;
ii) PTH, BMP или гибридный пептид, состоящий, по меньшей мере, из двух доменов, где первый домен содержит PTH или BMP, а второй домен содержит субстрат, способный к образованию поперечных связей; и
iii) контрастное вещество.
19. Композиция по п.18, где PTH представляет собой PTH1-34.
20. Композиция по любому из пп.18-19, где контрастное вещество выбрано из группы, состоящей из иодиксанола, иогексола, иопамидола, иопентола, иопромида, иорнепрола, иосимида, иотасула, иотролана, иоверсола, иоксилана и метризамида.
21. Композиция по п.20, где контрастное вещество представляет собой иогексол.
22. Композиция по любому из пп.18 или 21, где композиция, способная к образованию матрикса, содержит более одного компонента, и где композиция предоставляется в виде набора, в котором, по меньшей мере, один из компонентов композиции, способных к образованию матрикса, хранится отдельно от других компонентов композиции.
23. Дополненный матрикс, содержащий природное или синтетическое матриксное вещество, выбранное из группы, состоящей из PTH и BMP, и контрастное вещество, где матриксное вещество выбрано из группы, состоящей из матриксного вещества, включающего в себя фибрин; и/или матриксного вещества, полученного в результате реакции присоединения Майкла между первой исходной молекулой, содержащей n нуклеофильных групп, и второй исходной молекулой, содержащей m электрофильных групп, где n и m, по меньшей мере, равны двум, а сумма n+m составляет по меньшей мере пять.
24. Дополненный матрикс по п.23, где дополненный матрикс получают из композиции, способной к образованию матрикса, и гибридного пептида, содержащего биоактивный фактор в первом домене, и субстрат, способный образовывать ковалентные поперечные связи, во втором домене.
25. Дополненный матрикс по п.23 или 24, где PTH выбран из группы, состоящей из PTH1-84, PTH1-28, PTH1-34, PTH1-31 и PTH1-25.
26. Дополненный матрикс по п.25, где PTH представляет собой PTH1-34.
27. Дополненный матрикс по п.23, где BMP представляет собой BMP2 или BMP7.
28. Дополненный матрикс по п.23, где второй домен гибридного пептида содержит домен субстрата трансглутаминазы.
29. Дополненный матрикс по п.28, где домен субстрата трансглутаминазы представляет собой домен субстрата фактора XIIIa.
30. Набор, содержащий фибриноген, тромбин, источник кальция, биоактивный фактор, выбранный из группы, состоящей из PTH и BMP, и контрастное вещество.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64183005P | 2005-01-06 | 2005-01-06 | |
US60/641,830 | 2005-01-06 | ||
US64284805P | 2005-01-10 | 2005-01-10 | |
US60/642,848 | 2005-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007129845A true RU2007129845A (ru) | 2009-02-20 |
Family
ID=36572036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007129845/15A RU2007129845A (ru) | 2005-01-06 | 2006-01-06 | Местное лечение костных дефектов с помошью вмр или ртн, высвобождаемых из матрикса |
Country Status (11)
Country | Link |
---|---|
US (1) | US8318674B2 (ru) |
EP (1) | EP1833505B1 (ru) |
JP (1) | JP2008526811A (ru) |
KR (1) | KR20070108868A (ru) |
AU (1) | AU2006204462A1 (ru) |
BR (1) | BRPI0606408A2 (ru) |
CA (1) | CA2592877A1 (ru) |
ES (1) | ES2476996T3 (ru) |
MX (1) | MX2007008329A (ru) |
RU (1) | RU2007129845A (ru) |
WO (2) | WO2006073711A2 (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
EP1833522B1 (en) * | 2005-01-06 | 2016-06-22 | Kuros Biosurgery AG | Supplemented matrices for the repair of bone fractures |
BRPI0712910B8 (pt) | 2006-05-26 | 2021-05-25 | Baxter Int | sistema de múltiplos componentes para uma composição de aumento ósseo injetável, e, composição de aumento ósseo injetável |
EP2021043B1 (en) * | 2006-05-26 | 2011-01-12 | Baxter International Inc. | Injectable bone void filler |
AU2014200027B2 (en) * | 2007-03-26 | 2015-10-29 | Baxter Healthcare Sa | Injectable void filler for soft tissue augmentation |
US20080241072A1 (en) | 2007-03-26 | 2008-10-02 | Baxter International Inc. | Injectable void filler for soft tissue augmentation |
EP2155874B1 (en) | 2007-04-09 | 2016-05-11 | The Board Of Trustees Of The University Of Arkansas | Fusion proteins of collagen-binding domain and parathyroid hormone |
MX2009011005A (es) | 2007-04-13 | 2009-11-02 | Kuros Biosurgery Ag | Sellador polimerico para tejido. |
US8062364B1 (en) | 2007-04-27 | 2011-11-22 | Knee Creations, Llc | Osteoarthritis treatment and device |
WO2009047361A2 (en) * | 2007-10-12 | 2009-04-16 | Kuros Biosurgery Ag | Injectable fibrin compositions for tissue augmentation comprising strontium salt |
WO2009083544A2 (en) * | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
EP2279021B1 (en) | 2008-04-18 | 2013-02-13 | Kuros Biosurgery AG | Dispensing device, kit containing the device, and method of operating the device |
CN101868245B (zh) * | 2008-05-16 | 2013-10-23 | 全南大学校产学协力团 | 含有用于刺激成骨细胞分化的骨形成肽1(bfp1)的合成肽及含有上述合成肽的药物组合物 |
US8025872B2 (en) | 2008-05-16 | 2011-09-27 | Industry Foundation Of Chonnam National University | Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same |
WO2009154330A1 (en) * | 2008-06-20 | 2009-12-23 | Industry Foundation Of Chonnam National University | An synthetic peptide containing bone forming peptide 2(bfp 2) for stimulating osteoblast differentiation, and pharmaceutical composition comprising the synthetic peptide |
EP2311482A1 (en) * | 2009-10-12 | 2011-04-20 | Industry Foundation Of Chonnam National University | Osteogenic synthetic BMP-7 peptides, pharmaceutical compositions cell culture medium containing same |
US9717779B2 (en) * | 2011-01-31 | 2017-08-01 | Warsaw Orthopedic, Inc. | Implantable matrix having optimum ligand concentrations |
WO2012123028A1 (en) | 2011-03-16 | 2012-09-20 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
WO2013120060A1 (en) | 2012-02-09 | 2013-08-15 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
CA2859412C (en) | 2011-12-14 | 2021-05-25 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments |
US9550012B2 (en) | 2013-08-05 | 2017-01-24 | University Of Notre Dame Du Lac | Tissue scaffolds having bone growth factors |
US20180214572A1 (en) * | 2014-11-10 | 2018-08-02 | Ethris Gmbh | Induction of osteogenesis by delivering bmp encoding rna |
GB2545880A (en) * | 2015-10-20 | 2017-07-05 | Glide Pharmaceutical Tech Ltd | Solid formulation |
AU2017204355B2 (en) | 2016-07-08 | 2021-09-09 | Mako Surgical Corp. | Scaffold for alloprosthetic composite implant |
JP7397440B2 (ja) | 2017-02-10 | 2023-12-13 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | コラーゲン結合薬剤組成物およびその使用方法 |
EP3536353A1 (en) * | 2018-03-09 | 2019-09-11 | Kuros Biosurgery AG | Method and kits for producing a fibrin matrix |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086196A (en) * | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
SE8200751L (sv) * | 1982-02-09 | 1983-08-10 | Olle Larm | Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter |
DE3433210C1 (de) * | 1984-09-10 | 1986-06-05 | Hans Dr.med. Dr.med.dent. 8000 München Scheicher | Mittel zur Fuellung von Knochen- und Zahndefekten,zum Knochenaufbau,fuer Knochenkontaktschichten und fuer Knochen- und Zahnwurzelersatz und Verwendung von Carbonatapatit fuer diesen Zweck |
IL74617A (en) * | 1985-03-15 | 1988-11-15 | Yeda Res & Dev | Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals |
WO1989000051A1 (en) | 1987-07-07 | 1989-01-12 | Cytrx Biopool Ltd. | Fibrin-binding compound and method |
US5504001A (en) * | 1987-11-25 | 1996-04-02 | Zymogenetics, Inc. | Hybrid plasminogen activator |
US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5100668A (en) * | 1988-06-14 | 1992-03-31 | Massachusetts Institute Of Technology | Controlled release systems containing heparin and growth factors |
US5137819A (en) * | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
DE68928532T2 (de) | 1988-11-09 | 1998-05-28 | Protein Polymer Tech Inc | Funktionelles, durch ein rekombinantes verfahren hergestelltes synthetisches proteinpolymer |
US5171670A (en) * | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
US5169764A (en) | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
ATE212554T1 (de) | 1990-11-27 | 2002-02-15 | American Nat Red Cross | Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6559119B1 (en) * | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
SE9101853D0 (sv) | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
AU675051B2 (en) * | 1991-09-05 | 1997-01-23 | Baxter International Inc. | Topical fibrinogen complex |
SE470006B (sv) * | 1991-09-26 | 1993-10-25 | Corline Systems Ab | Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet |
US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
US5589452A (en) * | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US5310538A (en) * | 1993-03-11 | 1994-05-10 | Sterling Winthrop Inc. | Compositions of iodophenoxy alkylene ethers in film-forming materials for visualization of the gastrointestinal tract |
WO1994020133A1 (en) | 1993-03-12 | 1994-09-15 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
TW303299B (ru) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5428014A (en) * | 1993-08-13 | 1995-06-27 | Zymogenetics, Inc. | Transglutaminase cross-linkable polypeptides and methods relating thereto |
US5773577A (en) | 1994-03-03 | 1998-06-30 | Protein Polymer Technologies | Products comprising substrates capable of enzymatic cross-linking |
WO1996006181A1 (fr) | 1994-08-23 | 1996-02-29 | Drug Delivery System Institute, Ltd. | Procede de modification de proteine |
AU717906B2 (en) | 1994-12-07 | 2000-04-06 | American National Red Cross, The | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
US5693341A (en) * | 1995-03-16 | 1997-12-02 | Collagen Corporation | Affinity bound collagen matrices for the delivery of biologically active agents |
US5561982A (en) * | 1995-05-02 | 1996-10-08 | Universal Vortex, Inc. | Method for energy separation and utilization in a vortex tube which operates with pressure not exceeding atmospheric pressure |
JP2000500019A (ja) * | 1995-11-16 | 2000-01-11 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ストレプトアビジン融合タンパク質経由でのペプチドの生産方法 |
US7026292B1 (en) * | 1995-12-12 | 2006-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
CA2239775C (en) * | 1995-12-18 | 2008-07-15 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
US5874308A (en) * | 1996-01-16 | 1999-02-23 | University Of British Columbia | Compositions and methods for modulating cell proliferation using growth factor-polysaccharide binding fusion proteins |
US6221854B1 (en) * | 1996-03-05 | 2001-04-24 | Orquest, Inc. | Method of promoting bone growth with hyaluronic acid and growth factors |
US6026957A (en) * | 1996-03-27 | 2000-02-22 | The Procter & Gamble Company | Flexible paper covered package and process for producing same |
US5877153A (en) * | 1996-06-11 | 1999-03-02 | Commonwealth Biotechnologies Inc. | Heparin-binding peptides |
EP0950665A4 (en) | 1996-09-26 | 2004-05-06 | Ajinomoto Kk | PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM |
WO1998043686A1 (en) * | 1997-04-03 | 1998-10-08 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
AU748271B2 (en) | 1997-12-18 | 2002-05-30 | Eli Lilly And Company | Crystalline teriparatide |
US5958874A (en) * | 1998-02-18 | 1999-09-28 | The Research Foundation Of State University Of New York | Recombinant fibronectin-based extracellular matrix for wound healing |
DE19816858A1 (de) | 1998-04-16 | 1999-10-21 | Merck Patent Gmbh | Tricalciumphosphathaltige Biozementpasten mit Kohäsionspromotoren |
AR033639A1 (es) * | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
US7601685B2 (en) * | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
EP2311895B1 (en) | 1999-02-01 | 2017-04-12 | Eidgenössische Technische Hochschule Zürich | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
AU3438199A (en) | 1999-04-22 | 2000-11-10 | Eth Zurich | Controlled release of growth factors from heparin containing matrices |
WO2001000792A1 (en) * | 1999-06-29 | 2001-01-04 | Marchosky J Alexander | Compositions and methods for forming and strengthening bone |
US7052856B2 (en) * | 1999-10-05 | 2006-05-30 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
DE20010297U1 (de) | 2000-06-08 | 2000-08-31 | Eth Zuerich Zuerich | Enzymvermittelte Modifizierung von Fibrin zur Gewebemanipulation: Fibrin-Formulierungen mit Peptiden |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
CA2367636C (en) * | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
ATE420670T1 (de) | 2001-04-25 | 2009-01-15 | Eidgenoess Tech Hochschule | Arzneimittel freisetzende matrizen zur förderung der wundheilung |
WO2003040235A1 (en) * | 2001-11-07 | 2003-05-15 | Universität Zürich | Synthetic matrix for controlled cell ingrowth and tissue regeneration |
US7247609B2 (en) * | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
JP4560291B2 (ja) * | 2001-12-18 | 2010-10-13 | イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ | 組織操作のための成長因子改変タンパク質マトリクス |
AU2002361860A1 (en) * | 2001-12-21 | 2003-07-15 | Richard J. Lagow | Calcium phosphate bone replacement materials and methods of use thereof |
AU2003226688B2 (en) * | 2002-03-22 | 2009-08-13 | Kuros Biosurgery Ag | Composition for hard tissue augmentation |
AU2003225212A1 (en) * | 2002-04-29 | 2003-11-17 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
US20040002770A1 (en) * | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
WO2004071543A1 (en) * | 2003-02-13 | 2004-08-26 | Synthes Ag Chur | Injectable bone-replacement mixture |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
DE10355992A1 (de) * | 2003-11-27 | 2005-06-30 | Curasan Ag | Bioresorbierbares Kompositmaterial |
WO2006067221A2 (en) * | 2004-12-22 | 2006-06-29 | Kuros Biosurgery Ag | Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors |
-
2005
- 2005-12-14 WO PCT/US2005/045287 patent/WO2006073711A2/en active Application Filing
-
2006
- 2006-01-06 CA CA002592877A patent/CA2592877A1/en not_active Abandoned
- 2006-01-06 BR BRPI0606408-6A patent/BRPI0606408A2/pt not_active IP Right Cessation
- 2006-01-06 EP EP06701133.8A patent/EP1833505B1/en active Active
- 2006-01-06 JP JP2007549893A patent/JP2008526811A/ja active Pending
- 2006-01-06 US US11/326,924 patent/US8318674B2/en active Active
- 2006-01-06 KR KR1020077018080A patent/KR20070108868A/ko not_active Application Discontinuation
- 2006-01-06 ES ES06701133.8T patent/ES2476996T3/es active Active
- 2006-01-06 RU RU2007129845/15A patent/RU2007129845A/ru not_active Application Discontinuation
- 2006-01-06 AU AU2006204462A patent/AU2006204462A1/en not_active Abandoned
- 2006-01-06 MX MX2007008329A patent/MX2007008329A/es not_active Application Discontinuation
- 2006-01-06 WO PCT/EP2006/050070 patent/WO2006072623A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
MX2007008329A (es) | 2008-01-16 |
ES2476996T3 (es) | 2014-07-15 |
EP1833505A1 (en) | 2007-09-19 |
BRPI0606408A2 (pt) | 2009-06-23 |
WO2006073711A2 (en) | 2006-07-13 |
JP2008526811A (ja) | 2008-07-24 |
US20070010440A1 (en) | 2007-01-11 |
WO2006072623A1 (en) | 2006-07-13 |
AU2006204462A1 (en) | 2006-07-13 |
WO2006073711A3 (en) | 2007-03-01 |
KR20070108868A (ko) | 2007-11-13 |
EP1833505B1 (en) | 2014-04-02 |
US8318674B2 (en) | 2012-11-27 |
CA2592877A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007129845A (ru) | Местное лечение костных дефектов с помошью вмр или ртн, высвобождаемых из матрикса | |
Van Hoorick et al. | (Photo-) crosslinkable gelatin derivatives for biofabrication applications | |
Stratesteffen et al. | GelMA-collagen blends enable drop-on-demand 3D printablility and promote angiogenesis | |
Stichler et al. | Double printing of hyaluronic acid/poly (glycidol) hybrid hydrogels with poly (ε-caprolactone) for MSC chondrogenesis | |
Costantini et al. | 3D bioprinting of BM-MSCs-loaded ECM biomimetic hydrogels for in vitro neocartilage formation | |
BR0210282A (pt) | Veìculos de distribuição de fosfato de cálcio para proteìnas osteoindutivas | |
BRPI0619522B8 (pt) | conjugados de objetivação de vetor-fosfolipídio, composição compreendendo os referidos conjugados, composição de agente de contraste para ultra-som e método para preparo de microvesícula cheia de gás compreendendo um fosfolipídio e de fabricação de conjugado de peptídeo-fosfolipídio tendo baixos níveis de tfa | |
JP2005517658A5 (ru) | ||
ES2661910T3 (es) | Fabricación de cuero y tejido a partir de materiales que contienen hidrolizados de proteínas y gelatinas | |
AR033978A1 (es) | Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas | |
BRPI0604967A (pt) | método de codificação de vìdeo baseado em múltiplas camadas, método de geração de uma seqüência de bits mediante codificação de um bloco de um quadro de vìdeo com uma diferença entre o bloco e um bloco previsto, mìdia de armazenamento, método de decodificação de um bloco atual de um quadro de vìdeo de um bloco previsto, método de decodificação de um bloco atual de um quadro de vìdeo a partir de um bloco previsto, método de decodificação de vìdeo baseado em múltiplas camadas, codificador de vìdeo baseado em múltiplas camadas, e decodificador de vìdeo baseado em múltiplas camadas | |
ATE541595T1 (de) | Zusammensetzung für die verstärkung von hartem gewebe | |
DE60043271D1 (de) | Methoden und Zusammensetzungen zur Heilung und Reparatur von Gelenkknorpeln | |
BRPI0810530B8 (pt) | composição, uso da mesma, biomaterial sintético, seu método de fabricação e kit para formar o mesmo | |
RU2014123990A (ru) | Антитело к адреномедуллину (adm) или фрагмент анти-adm антитела, или анти-adm he-iq каркас для применения в терапии | |
Carr et al. | Single nonfouling hydrogels with mechanical and chemical functionality gradients | |
PT884052E (pt) | Materiais indutores de cartilagem/caso para reparacao | |
BRPI0406924A (pt) | Composições de fragrância | |
Wang et al. | Molecularly engineered protein glues with superior adhesion performance | |
DE602004001445D1 (de) | Zusammensetzungen mit fluorierten kohlenwasserstoffen und oxygenierten lösungsmitteln | |
Jin et al. | Influence of postwashing process on the elution of residual monomers, degree of conversion, and mechanical properties of a 3D printed crown and bridge materials | |
ATE255920T1 (de) | Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln | |
BR0013589A (pt) | Processo para produzir pneumáticos para rodas de veìculo, pneumático para rodas de veìculo, composição elastomérica reticulável, e, produto elastomérico reticulado | |
Zhang et al. | Stimuli responsive deswelling of radiation synthesized collagen hydrogel in simulated physiological environment | |
CA2913405A1 (en) | Compositions comprising a polymer-protein conjugate and an environmentally-responsive polymer and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100209 |